ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.81
+0.18 (2.09%)
At close: Oct 28, 2026, 4:00 PM EDT
8.80
-0.01 (-0.11%)
Pre-market: Oct 29, 2026, 4:41 AM EDT
ImmunityBio Employees
As of December 31, 2025, ImmunityBio had 691 total employees, including 684 full-time and 7 part-time employees. The number of employees increased by 11 or 1.62% compared to the previous year. That makes ImmunityBio the 17,605th largest employer in the world and 2,432nd in the United States.
Employees
691
Change (1Y)
11
Growth (1Y)
1.62%
Revenue / Employee
$239,931
Profits / Employee
-$1,436,117
Market Cap
9.34B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 691 | 11 | 1.62% | 684 | 7 |
| Sep 30, 2025 | 673 | 1 | 0.15% | 673 | 0 |
| Jun 30, 2025 | 685 | 63 | 10.13% | 685 | 0 |
| Mar 31, 2025 | 671 | 43 | 6.85% | 671 | 0 |
| Dec 31, 2024 | 680 | 52 | 8.28% | 680 | 0 |
| Sep 30, 2024 | 672 | 2 | 0.30% | 672 | 0 |
| Jun 30, 2024 | 622 | -61 | -8.93% | 622 | 0 |
| Mar 31, 2024 | 628 | -75 | -10.67% | 628 | 0 |
| Dec 31, 2023 | 628 | -97 | -13.38% | 628 | 0 |
| Sep 30, 2023 | 670 | -90 | -11.84% | 670 | 0 |
| Jun 30, 2023 | 683 | -57 | -7.70% | 683 | 0 |
| Mar 31, 2023 | 703 | 15 | 2.18% | 703 | 0 |
| Dec 31, 2022 | 725 | 138 | 23.51% | 725 | 0 |
| Sep 30, 2022 | 760 | 222 | 41.26% | 760 | 0 |
| Jun 30, 2022 | 740 | 229 | 44.81% | 740 | 0 |
| Mar 31, 2022 | 688 | 213 | 44.84% | 688 | 0 |
| Dec 31, 2021 | 587 | 138 | 30.73% | 587 | 0 |
| Sep 30, 2021 | 538 | 273 | 103.02% | 538 | 0 |
| Jun 30, 2021 | 511 | 246 | 92.83% | 511 | 0 |
| Mar 31, 2021 | 475 | 210 | 79.25% | 475 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Twist Bioscience | 979 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| TG Therapeutics | 399 |
| Krystal Biotech | 295 |
IBRX News
- 7 days ago - ImmunityBio announces database lock for Cohort A of QUILT-2.005 - TheFly
- 7 days ago - ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer - Business Wire
- 9 days ago - ImmunityBio falls -5.7% - TheFly
- 12 days ago - ImmunityBio announces publication of long-term data from QUILT-3.032 study - TheFly
- 12 days ago - ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors - Business Wire
- 14 days ago - ImmunityBio price target raised to $14 from $12 at Jefferies - TheFly
- 14 days ago - ImmunityBio says FDA expands approval indication for ANKTIVA-BCG combo - TheFly
- 14 days ago - FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease - Business Wire